Hemocyanins as immunostimulants

Del Campo M, Arancibia S, Nova E, Salazar F, González A, Moltedo B, De Ioannis P, Ferreira J, Manubens A, Becker MI.

Rev Med Chil. 2011 Feb;139(2):236-46. Epub 2011 Jul 11

Superficial bladder cancer therapy

Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D.

ScientificWorldJ (2004) 4 (S1), 387–399

Laboratory and clinical experience with keyhole limpet hemocyanin (Immucothel(r)) in superficial bladder cancer

Lamm.

J Urol Urogynäkol (Österreich) 2003; 10 (2): 18–21

In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin

Riggs DR, Jackson B, Vona-Davis L, McFadden D.

J Surg Res. 2002 Dec;108(2):279-84

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.

Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Ruecker A, Müller S,Sauerbruch T, Schmidt-Wolf IG.

Cancer Immunol Immunother. 2002 Dec;51(11-12):637-44. Epub 2002 Oct 3.

Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study

Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF.

Eur Urol. 2000;37 Suppl 3:45-9

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

Lamm DL, Dehaven JI, Riggs DR.

Eur Urol. 2000;37 Suppl 3:41-4

Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma

Echarti C, Jurincic-Winkler CD, Klippel KF.

Eur Urol. 2000;37 Suppl 3:50-3

Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results

Linn JF, Black P, Derksen K, Rübben H, Thüroff JW

Eur Urol. 2000;37 Suppl 3:34-40

Immunotherapy of bladder cancer

Nseyo UO, Lamm DL.

Semin Surg Oncol. 1997 Sep-Oct; 13(5):342-9